Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 30, 2024

SELL
$41.99 - $62.38 $8,733 - $12,975
-208 Reduced 75.64%
67 $3,000
Q3 2023

Oct 26, 2023

BUY
$27.8 - $45.35 $7,645 - $12,471
275 New
275 $11,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Macroview Investment Management LLC Portfolio

Follow Macroview Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macroview Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Macroview Investment Management LLC with notifications on news.